



Science Report 2017



www.profil.com



Dr Tim Heise
Lead Scientist
Chairman of the Board of Directors
Co-Founder Profil Germany

Preface

I am very proud to present the Profil Science Report 2017. As in the last years, our Science Report impressively documents the sound scientific expertise standing of Profil. With 49 scientific publications (cumulated impact factor of > 300) and 70 scientific presentations at international meetings, our publication record at Profil can easily compete with that of many academic institutions. By being part of transdisciplinary knowledge and innovation communities such as CBmed and EIT Health we contribute to shaping cutting-edge innovations in methods development, diabetes technology, and healthcare provision.

The extensive list of our scientific and innovative activities in 2017 indicates the reputation of Profil. We have a proven track record for outstanding presentations of clinical trial results to both the scientific and the business world as well as to boards and regulatory bodies. We are convinced that scientific excellence (in combination with regulatory know how, operational efficiency, and a high commitment to quality) is key for optimally designing and conducting clinical studies, and therefore is the basis for the high client satisfaction that we are so proud of.

In addition, we are much obliged to the many healthy people and patients with type 1 or type 2 diabetes that participate in our studies and thereby make a huge contribution to the development of better drugs and devices for the treatment of diabetes and obesity. In order to get the best possible result from their efforts, we are committed to making the results of our studies available to the scientific community.

We look very much forward to interacting with patients, physicians, scientists and people from industry to continue and further expand our scientific activities in the next couple of years. We will not relent in our efforts to serve our customers' needs even better and to make our contribution for a better life of people with diabetes all over the world.

Content

Science Report 2017	1
Preface	2
Content	3
Metrics	4
Scientific Publications	6
Original Articles	6
Reviews	13
Letters / Comments	15
Scientific Presentations	16
Oral Presentations	16
Poster Presentations	22
Advanced Training Courses	27
Science Circle	27
Trainings Clinical Pharmacology	29
Granted Research Consortia	31
Scientific Communication	34
Webinars	34
Blogs	35
Media Reports (Selection)	39

Metrics

TABLE 1: TOTAL OUTPUT

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	50	310,814	6,216
Original Articles	36	270,705	7,520
Reviews	8	38,256	4,782
Letters/Comments	6	1,853	0,309
Scientific Congress Presentations	72	n/a	n/a
Orals	42	n/a	n/a
Poster	30	n/a	n/a
Advanced Trainings	21	n/a	n/a
Granted Research Consortia	4	n/a	n/a
Scientific Communication	58+	n/a	n/a
Webinars	4	n/a	n/a
Blogs	44	n/a	n/a
Media Reports	10+	n/a	n/a

TABLE 2: PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	28	100,148	3,453
Original Articles	16	82,835	4,749
Reviews	6	15,460	2,577
Letters/Comments	6	1,853	0,309
Scientific Congress Presentations	58	n/a	n/a
Orals	39	n/a	n/a
Poster	19	n/a	n/a

TABLE 3: PUBLISHED STUDIES (PARTLY) OPERATED BY PROFIL

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	31	142,243	4,588
Original Articles	31	142,243	4,588
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
Scientific Congress Presentations	44	n/a	n/a
Orals	22	n/a	n/a
Poster	22	n/a	n/a

TABLE 4: PUBLISHED STUDIES (PARTLY) OPERATED BY PROFIL
+ PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR

	Count	Σ Impact Factors	Mean Impact Factor
Scientific Publications	16	75,978	4,873
Original Articles	16	75,978	4,873
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
Scientific Congress Presentations	35		
Orals	20	n/a	n/a
Poster	15	n/a	n/a

Scientific Publications

Original Articles

1. Kapitza, C., Dahl, K., Jacobsen, J.B., Axelsen, M.B., Flint, A.
Effects of semaglutide on beta-cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
Diabetologia 60(8): 1390-1399, 2017
IF(2016): 6,080
2. Engeli, S., Stinkens, R., Heise, T., May, M., Goossens, G.H., Blaak, E.E., Havekes, B., Jax, T., Albrecht, D., Pal, P., Tegtbur, U., Haufe, S., Langenickel, T.H., Jordan, J.
Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension.
Hypertension 71(1): 70-77, 2018
IF(2016): 6,857
3. Hövelmann, U., Bysted, B.V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D.V., Heise, T.
Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog.
Diabetes Care 37(5): 503-509, 2017
IF(2016): 11,857
4. Moser, O., Eckstein, M.L., McCarthy, O., Deere, R., Bain, S.C., Haahr, H.L., Zijlstra, E., Bracken, R.M.
Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes.
Diabetology & Metabolic Syndrome 9:93; doi: 10.1186/s13098-017-0294-1, 2017
IF(2016): 2,347
5. Kenny, H.C., Rudwill, F., Breen, L., Salanova, M., Blottner, D., Heise, T., Heer, M., Blanc, S., O'Gorman, D.J.
Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistance.
Diabetologia 60(8): 1491-1501, 2017
IF(2016): 6,080

6. Meier, J.J., Schenker, N., Kahle, M., Schliess, F., Kapitza, C., Menge, B.A.
Impact of insulin glargine and lixisenatide on beta-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
Diabetes Obes. Metab. 19(11): 1625-1629, 2017
IF(2016): 6,715

7. Ruan, Y., Thabit, H., Leelarathna, L., Hartnell, S., Wilinska, M.E., Tauschmann, M., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Evans, M.L., Pieber T.R., Arnolds, S., Hovorka, R., AP@home consortium.
Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes.
Diabetes Obes. Metab. 19(10): 1485-1489, 2017
IF(2016): 6,715

8. Zijlstra, E., Jahnke, J., Fischer, A., Kapitza, C., Forst, T.
Impact of injection speed, volume, and site on pain sensation.
J. Diabetes Sci. Technol. doi: 10.1177/1932296817735121, epub ahead of print, 2017
IF(2016): -

9. Barnard, K.D., Kropff, J., Choudhary, P., Neupane, S., Bain, S.C., Kapitza, C., Forst, T., Link, M., Mdingi, C., DeVries, J.H.
Acceptability of implantable continuous glucose monitoring sensor.
J. Diabetes Sci. Technol. doi: 10.1177/1932296817735123, epub ahead of print, 2017
IF(2016): -

10. Heise, T., Kaplan, K., Haahr, H.L.
Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/mL and 300 U/mL): a comparison across studies.
J. Diabetes Sci. Technol. doi: 10.1177/1932296817731422, epub ahead of print, 2017
IF(2016): -

11. Zijlstra, E., Demissie, M., Graungaard, T., Heise, T., Nosek, L., Bode, B.
Investigation of pump compatibility of fast-acting insulin aspart in subjects with type 1 diabetes.
J. Diabetes Sci. Technol. doi: 10.1177/1932296817730375, epub ahead of print, 2017
IF(2016): -

12. Barnard, K.D., Wysocki, T., Ullly, V., Mader, J.K., Pieber, T.R., Thabit, H., Tauschmann, M., Leelarathna, L., Hartnell, S., Acerini, C.L., Wilinska, M.E., Dellweg, S., Benesch, C., Arnolds, S., Holzer, M., Kojzar, H., Campbell, F., Yong, J., Pichierri, J., Hindmarsh, P., Heinemann, L., Evans, M.L., Hovorka, R.H. Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. **J. Diabetes Sci. Technol.** 11(6): 1080-1088, 2017
IF(2016): -
13. Harris, C., Forst, T., Heise, T., Plum-Mörschel, L., Watkins, E., Zhang, Q., Fan, L., Garhyan, P., Porksen, N. Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial: IMAGINE 8. **Diabetes Technol. Ther.** 19(8): 463-470, 2017
IF(2016): 2,698
14. Emami, A., Willinska, M.E., Thabit, H., Leelarathna, L., Hartnell, S., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Pieber, T.R., Arnolds, S., Evans M.L., Hovorka, R. Behavioral patterns and associations with glucose control during 12-Week randomized free-living clinical trial of day and night hybrid closed-loop insulin delivery in adults with type 1 diabetes. **Diabetes Technol. Ther.** 19(7): 433-437, 2017
IF(2016): 2,698
15. Bally, L., Thabit, H., Ruan, Y., Mader, J.K., Kojzar, H., Dellweg, S., Benesch, C., Hartnell, S., Leelarathna, L., Wilinska, M.E., Evans, M.L., Arnolds, S., Pieber, T.R., Hovorka, R. Bolusing frequency and amount impacts glucose control during hybrid closed-loop. **Diabet. Med.** doi: 10.1111/dme.13436, epub ahead of print, 2017
IF(2016): 3,054
16. Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S.S., Woerle, H.J., Broedl, U.C. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type 2 diabetes mellitus. **J. Am. Soc. Hypertens.** 11(9): 604-612, 2017
IF(2016): 3,263

17. Wysham, C., Bonadonna, R.C., Aroda, V.R., Puig Domingo, M., Kapitza, C., Stager, W., Yu, C., Niemoeller, E., Souhami, E., Bergenstal, R.M., LixiLan-L trial investigators.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Diabetes Obes. Metab. 19(10): 1408-1415, 2017
IF(2016): 6,715
18. Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., Chan, J.C., Choi, J., Gustavson, S.M., Iqbal, N., Maggioni, A.P., Marso, S.P., Öhman, P., Pagidipati, N.J., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A.F., EXSCEL Study Group (including Forst, T.)
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.
N. Engl. J. Med. 377(13): 1228-1239, 2017
IF(2016): 72,406
19. Heise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., Haahr, H.L.
Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Diabetes Obes. Metab. 19(7): 1032-1039, 2017
IF(2016): 6,715
20. Heise, T., Pieber, T.R., Danne, T., Erichsen, L., Haahr, H.
A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes.
Clin. Pharmacokinet. 56(5): 551-559, 2017
IF(2016): 5,216
21. Hövelmann, U., Heise, T., Nosek, L., Sassenfeld, B., Thomsen, K.M.D., Haahr, H.
Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions.
Clin. Drug Investig. 37(5): 503-509, 2017
IF(2016): 1,853
22. Lind, M., Polonsky, W., Hirsch, I.B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A.F., Frid, A., Wedel, H., Ahlén, E., Nyström, T., Hellman, J.
Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial.
JAMA 317(4): 379-387, 2017
IF(2016): 44,400

23. Forst, T., Falk, A., Andersen, G., Fischer, A., Weber, M.M., Voswinkel, S., Heise, T., Kapitza, C., Plum-Mörschel, L.
Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Diabetes Obes. Metab. 19(4): 489-495, 2017
IF(2016): 6,715

24. Kuhlenkötter, M., Heise, T., Benesch, C.
Improved algorithm for automated glucose clamps.
Diabetes Technol. Ther. 19(2): 124-130, 2017
IF(2016): 2,698

25. Kapitza, C., Nowotny, I., Lehmann A., Bergmann, K., Rotthaeuser, B., Nosek, L., Becker, R.H.A.
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
Diabetes Obes. Metab. 19(5): 622-627, 2017
IF(2016): 6,715

26. de la Peña, A., Loghin, C., Cui, X., Zhang, X., Kapitza, C., Kelly, R.P.
Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
Diabetes Obes. Metab. 19(4): 517-523, 2017
IF(2016): 6,715

27. Porksen, N., Linnebjerg, H., Garhyan, P., Lam, E.C., Knadler, M.P., Jacober, S.J., Hövelmann, U., Plum-Mörschel, L., Watkins, E., Gastaldelli, A., Heise, T.
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Diabetes Obes. Metab. 19(4): 482-488, 2017
IF(2016): 6,715

28. Heise, T., Stender-Petersen, K., Hövelmann, U., Jacobsen, J.B., Nosek, L., Zijlstra, E., Haahr, H.
Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus.
Clin. Pharmacokinet. 56(6): 649-660, 2017
IF(2016): 5,216

29. Siegmund, T., Pfohl, M., Forst, T., Pscherer, S., Bramlage, P., Foersch, J., Borck, A., Seufert, J.
Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - a prospective observational study in 2202 patients.
Diabetes Metab. Syndr. 11(1): 51-57, 2017
IF(2016): 1,810
30. Heise, T., Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Haahr, H.
A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus.
Drugs Aging 34(1): 29-38, 2017
IF(2016): 2,769
31. Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S.C., Kapitza, C., Forst, T., Link, M., Dehennis, A., DeVries, J.H.
Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial.
Diabetes Care 40(1): 63-68, 2017
IF(2016): 11,857
32. Heise, T., Zijlstra, E., Nosek, L., Rikte, T., Haahr, H.
Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial.
Diabetes Obes. Metab. 19(2): 208-215, 2017
IF(2016): 6,715
33. Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E.E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G.H., Langenickel, T.H.
Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension.
Clin. Pharmacol. Ther. 101(2): 254-263, 2017
IF(2016): 7,266
34. Leelarathna, L., Thabit, H., Hartnell, S., Willinska, M.E., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Evans, M.L., Arnolds, S., Pieber, T.R., Hovorka, R., AP@home Consortium.
Rapid benefits of structured optimization and sensor-augmented insulin pump therapy in adults with type 1 diabetes.
J. Diabetes Sci. Technol. 11(1): 180-181, 2017
IF(2016): -

35. Kann, P.H., Moll, R., Bartsch, D., Pfützner, A., Forst, T., Tamagno, G., Goebel, J.N., Fourkiotis, V., Bergmann, S.R., Collienne, M.
Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: indications and clinical relevance in a single investigator cohort of 47 patients.
Endocrine 56(1): 158-163, 2017
IF(2016): 3,131
36. Linnebjerg, H., Lam, E.C., Zhang, X., Seger, M.E., Coutant, D., Chua, L., Kapitza, C., Heise, T.
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Diabetes Obes. Metab. 19(1): 33-39, 2017
IF(2016): 6,715

Reviews

37. Davies, M., Dahl, D., Heise, T., Kiljanski, J., Mathieu, C.
Introduction of biosimilar insulins in Europe.
Diabet. Med. 34(10): 1340-1353, 2017
IF(2016): 3,054
38. Goldman, J., Kapitza, C., Pettus, J., Heise, T.
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Curr. Med. Res. Opin. 33(10): 1821-1831, 2017
IF(2016): 2,757
39. Riddell, M.C., Gallen, I.W., Smart, C.E., Taplin, C.E., Adolfsson, P., Lumb, A.N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R.J., Hume, C., Annan, F., Fournier, P.A., Graham, C., Bode, B., Galassetti, P., Jones, T.W., Millán, I.S., Heise, T., Peters, A.L., Petz, A., Laffel, L.M.
Exercise management in type 1 diabetes: a consensus statement.
Lancet Diabetes Endocrinol. 5(5): 377-390, 2017
IF(2016): 19,742
40. Forst, T., Plum-Mörschel, L., Weber, M.M.
Cardiovascular aspects of diabetes treatment: finally a reason for cardiologists to be pleased.
Internist 58(3): 293-302, 2017
IF(2016): 0,348
41. Forst, T., Plum –Mörschel, L.
Insulin Biosimilars – new but still familiar.
Kompodium Biosimilars 2:18-22, 2017
IF(2016): -
42. Haahr, H., Fita, E.G., Heise, T.
A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use.
Clin. Pharmacokinet. 56(4): 339-354, 2017
IF(2016): 5,216
43. Heise, T., Bister, T.
Pharmacological properties of faster-acting insulin aspart.
Diabetologie und Stoffwechsel 12(4): 386-396, 2017
IF(2016): 0,429

44. Heise, T., Mathieu, C.
Impact of the mode of protraction of basal insulin therapies on their
pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
Diabetes Obes. Metab. 19(1): 3-12, 2017
IF(2016): 6,715

Letters / Comments

45. Heise, T., Hövelmann, U., Nosek, L., Sassenfeld, B., Thomsen, K.M.D., Haahr, H.
Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas.
Clin. Drug Investig. doi: 10.1007/s40261-017-0539-7, epub ahead of print, 2017
IF(2016): 1,853

46. Forst, T., Jahnke, J.
Insulintherapie: Möglichkeiten, Grenzen und Entwicklungen.
ARS MEDICI Fortbildung 1+2: 37-42, 2017
IF(2016): -

47. Forst T.
Jenseits glukozentrischer Therapie.
Diabetes Congress Report 3: 14-18, 2017
IF(2016): -

48. Forst T.
Sulfonylharnstoffe – should I stay or should I go?
Diabetes Congress Report 4: 14-19, 2017
IF(2016): -

49. Forst T.
Adjuvante Therapie durch Hemmung der Natrium-Glukose-Transporter bei Patienten mit einem Diabetes mellitus Typ 1.
Diabetes Congress Report 5: 30-39, 2017
IF(2016): -

50. Forst T.
Insulinentwicklungen.
Diabetes Forum 10: 11-15, 2017
IF(2016): -

Scientific Presentations

Oral Presentations

CMC-BIO.NRW Workshop. MLM Medical Labs Mönchengladbach, Mönchengladbach, Germany, November 14, 2017

51. Arnolds, S.
Of pumps and sensors: on the way to an artificial pancreas.

11. Herbsttagung der Deutschen Diabetes Gesellschaft. Nürnberg, Germany, November 10 – 11, 2017

52. Heinemann, L.
“Bionik-Pankreas” – Leben ohne Hypoglykämie und Kohlenhydratmangel.
AGDT-Symposium: Diabetestechnologie: Quantensprung vom Sensor zum Closed Loop.

17th Annual Diabetes Technology Meeting, Bethesda, MD, November 2 – 4, 2017

53. Zijlstra, E.
Insulins in the pipeline.

DiaLate, Düsseldorf, Germany, October 27 – 28, 2017

54. Forst, T.
DiaLate (scientific lead).

DDG Weiterbildung “Klinische Diabetologie” Teil 1. October 16 – 20, 2017

55. Forst, T.
Pharmakokinetik, Galenik und Molekularstruktur der verschiedenen Insuline.
56. Forst, T.
Neue technische Entwicklungen in der Diabetologie.

12. Diabetes Forum – Gesundheitsverbund Braunschweig. Braunschweig, Germany, October 18, 2017

57. Zijlstra, E.
New insulins and the path to an artificial pancreas.

German EIT Health Symposium, Mannheim, Germany, October 4 – 5, 2017

58. Schliess, F.
The CLOSE EIT Health innovation project by design

15. Düsseldorfer Diabetestag. Handwerkskammer Düsseldorf, Düsseldorf, Germany, September 30, 2017

59. Arnolds, S.
Neue Forschungsansätze.

Global Scientific Expert Meeting (GSEM) organised by Novo Nordisk. Madrid, Spain, September 27 – 28, 2017

60. Zijlstra, E.
Reviewing the clinical pharmacology of faster aspart.
61. Zijlstra, E.
Reviewing the evidence of faster aspart during continuous subcutaneous insulin infusion.

16. Deutscher Kongress für Versorgungsforschung – Deutsches Netzwerk Versorgungsforschung e.V.. Berlin, Germany, October 4 – 6, 2017

62. Wilm, S., Bücken, B., Arnolds, S., Lachmann, N., Verket, M., Spörkel, O.
Was wünschen sich Menschen mit Diabetes?

51. Kongress für Allgemeinmedizin und Familienmedizin. Düsseldorf, Germany, September 21 – 23, 2017

63. Bücken, B., Wilms, S., Arnolds, S., Lachmann, N., Verket, M., Spörkel, O.
Was sind die Bedürfnisse und Wünsche von Menschen mit Diabetes mellitus in Nordrhein-Westfalen für den Bereich der Diabetesforschung?

Lilly Lisbon/Porto, Portugal, September 20 – 21, 2017

64. Forst, T.
Dulaglutide: the AWARD study program.

53. EASD Annual Meeting. Lisbon, Portugal, September 11 – 15, 2017

65. Plum-Mörschel, L., Heise, T., Zijlstra, E., Lyby, K., Wassermann, K., Brøndsted, L., Halberg, I.B.
Efficacy and safety of oral basal insulin: eight-week feasibility study in people with type 2 diabetes.
Diabetologia 60 (Suppl. 1): A-74, 2017

66. Zijlstra, E., Plum-Mörschel, L., Heise, T., Lyby, K., Wassermann, K., Halberg, I.B.
Effect of food intake on the absorption of oral basal insulin.
Diabetologia 60 (Suppl. 1): A-189, 2017
67. Kapitza, C., Löhr, J., Liu, R., Reddy, S., Dellva, M., Matzopoulos, M., Knadler, M., Loh, M., Hardy, T., Kadzda, C.
A novel formulation of insulin lispro shows significantly faster absorption and improvement in postprandial glucose excursions versus insulin lispro in patients with type 2 diabetes.
Diabetologia 60 (Suppl. 1): A-192, 2017
68. Heise, T.
Dexcom CGM outcome studies demonstrate reduction of HbA1c and hypoglycemia.
Session: Dexcom continuous glucose monitoring: clinical outcomes and next generation technology.

**InnoDiaCare EIT Health Summer School on Digital Innovation in Diabetes Care – Part 2.
University of Cologne, Germany, August 28 – September 2, 2017**

69. Schliess, F.
Diabetes – a paradigm for rewarding innovation in healthcare.

Going AP+ value concept design workshop. IESE Business School. Barcelona, Spain, July 10-11. 2017

70. Schliess, F.
CLOSE – automated glucose control at home for people with chronic disease.
Going artificial pancreas + (AP+).

**InnoDiaCare EIT Health Summer School on Digital Innovation in Diabetes Care – Part 1.
Medical University of Lodz, Poland, July 2 – 8, 2017**

71. Schliess, F.
The CLOSE Innovation by Design project.

CLOSE EIT On-site monitoring event. Air Liquide, Gentilly, France, June 23, 2017

72. Schliess, F.
The CLOSE innovation project by design: a paradigm case for living the knowledge triangle.

MedTech Summit. Nuremberg, Germany, June 21 – 22, 2017

73. Schliess, F.
Closed-loop metabolic control in diabetes care.

Qualitätszirkel der Düsseldorfer Diabetologen. Profil GmbH, Neuss, Germany, June 12, 2017

74. Arnolds, S.
Neue Substanzen und Profil ADA Beiträge.

ADA 77^h Scientific Sessions. San Diego, CA, June 9 – 12, 2017

75. Plum-Mörschel, L., Heise, T., Zijlstra, E., Lyby, K., Wassermann, K., Brøndsted, L., Halberg, I.B.
Efficacy and safety of oral basal insulin: eight-week feasibility study in people with type 2 Diabetes.
Diabetes 66 (Suppl. 1): 380-OR, 2017

52. Jahrestagung der Deutschen Diabetes Gesellschaft. Hamburg, Germany, May 24 – 27, 2017

76. Behrens, M., Weber, D., Kaltheuner, M., Heinemann, L., Faber-Heinemann, G.
Körperliche Aktivität bei 3.755 Patienten mit Typ 1-Diabetes: Ergebnisse von winMove – einer Sport- und Bewegungsanalyse.
Diabetologie und Stoffwechsel 12(S01):FV56, 2017
77. Heise, T.
Schneller – warum Fiasp® näher am physiologischen Insulinprofil ist.
Novo Nordisk Industriesymposium
78. Forst, T.
Evidenz für kausale Therapie der diabetischen Neuropathie. Komorbiditäten – Diabetische Neuropathie: Update 2017
79. Heinemann, L.
Was braucht es in Zukunft in Deutschland, um in der Diabetestechnologie fit zu sein?
Politik und Querschnittsthemen – Technik in der angewandten Diabetologie
80. Heinemann, L.
Politik und Querschnittsthemen – WinDiab Symposium (Vorsitz).
81. Adamszewski, H., Heinemann, L.,
Gestationsdiabetes – Schwangerschaft und Technologie: “fruchtbare” Interaktionen (Vorsitz).
82. Heinemann, L., Ickrath, M.
Politik und Querschnittsthemen – Digitalisierung in der Diabetestherapie (Vorsitz)

83. Heinemann, L.
Aus dem Blickwinkel des Wissenschaftlers.
Politik und Querschnittsthemen – Diabetes und Technologie: verschiedene
Blickwinkel.

**Global Scientific Expert Meeting (GSEM) organised by Novo Nordisk. Barcelona, Spain,
April 6 – 7, 2017**

84. Zijlstra, E.
Reviewing the clinical pharmacology of faster aspart.
85. Zijlstra, E.
Reviewing the evidence of faster aspart during continuous subcutaneous insulin
infusion.

Lilly Moscow, Russia, March 30 – April 4, 2017

86. Forst, T.
Dulaglutide: a new option for the treatment of T2DM.

DDG Kurs Mainz, Germany, March 24, 2017

87. Forst, T.
Neues aus Technologie und Pharmakotherapie.

Global Insulin Dialogue 2017. Novo Nordisk, Copenhagen, Denmark, March 2, 2017

88. Zijlstra, E.
The glucose clamp: a hands-on approach to understanding a core technique.

Diabetologische Fachgespräche, 8. Expertentreffen. Fulda, Germany, February 25, 2017

89. Zijlstra, E.
Neue Diabetestechnologien auf dem Weg zur technischen Heilung des Diabetes.

Basaglar Launch Event. Manila, Philippines, January 23 – 26, 2017

90. Forst, T.
Insulin glargine: the totality of evidence.

**10th International Conference on Advanced Technologies & Treatments for Diabetes.
Paris, France, February 15 – 18, 2017**

91. Zijlstra, E.
Clinical pharmacology of ultra-fast insulin in pumps.

**DiaTec 2017: Jahrestagung der AGDT und Fortbildung zur Diabetestechnologie,
Berlin, Germany, January 27 – 28, 2017**

92. Zijlstra, E.
Neue Insuline und deren Einsatz in der Pumpentherapie.

Poster Presentations

EIT Health Summit, London, UK, December 4 – 5, 2017

93. Schliess, F.
CLOSE – Automated glucose control at home for people with chronic disease

53. EASD Annual Meeting. Lisbon, Portugal, September 11 – 15, 2017

94. Moser, O., McCarthy, O., Deere, R., Eckstein, M.L., Bain, S.C., Haar, H.L., Zijlstra, E., Heise, T., Bracken, R.M.
Poor glycaemic control is associated with altered physiological responses during cardio-pulmonary exercise testing in type 1 diabetes.
Diabetologia 60 (Suppl. 1): A-686, 2017
95. Meiffren, G., Soula, O., Ranson, A., Gaudier, M., Alluis, B., Andersen, G., Lamers, D., Heise, T.
Ultra-rapid BioChaperone Lispro improves post-prandial blood glucose excursions versus insulin Lispro in a 14-day treatment study in subjects with type 1 diabetes.
Diabetologia 60 (Suppl. 1): A-686, 2017
96. Ólafsdóttir, A.F., Polonsky, W.H., Bolinder, J., Hirsch, I.B., Heise, T., Wedel, H., Dahlqvist, S., Lind, M.
Impact of continuous glucose monitoring (CGM) on hypoglycemia in T1D adults on multiple daily insulin injections (MDI).
Diabetologia 60 (Suppl. 1): A-715, 2017
97. Heise, T., Væver Bysted, B., Mouritzen, U., Hövelmann, U., Lamers, D., Vega Møller, D.
Dasiglucagon, a novel soluble glucagon analogue, successfully restores blood glucose levels after hypoglycaemia in people with type 1 diabetes.
Diabetologia 60 (Suppl. 1): A-738, 2017
98. Dvorak, R.V., Plum-Mörschel, L., Andersen, G., Kasparova, P., Arrubla, J., Edsberg, B.,
Co-administration of tesofensine/metoprolol: improvement in heart rate with significant weight reduction in overweight or obese subjects with type 2 diabetes.
Diabetologia 60 (Suppl. 1): A-851, 2017
99. Andersen, G., Heise, T., Edsberg, B., Lamers, D., Jacobsen, T., Plum-Mörschel, L., Dvorak, R.V.
Co-administration of tesofensine and metoprolol: improvements in body weight and liver fat content in patients with type 2 diabetes.
Diabetologia 60 (Suppl. 1): A-857, 2017

ADA 77th Scientific Sessions. San Diego, CA, June 9 – 12, 2017

100. Heise, T., Væver Bysted, B., Mouritzen, U., Hövelmann, U., Lamers, D., Vega Møller, D.
Dasiglucagon, a novel soluble glucagon analog, successfully restores blood glucose levels after hypoglycemia in people with type 1 diabetes mellitus (T1DM).
Diabetes 66 (Suppl 1): 389-P, 2017
101. Ólafsdóttir, A.F., Hirsch, I.B., Bolinder, J., Heise, T., Polonsky, W.H., Dahlqvist, S., Frid, A., Ahlen, E., Hellman, J., Wedel, H., Lind, M.
Impact of continuous glucose monitoring (CGM) on hypoglycemia in T1D adults on multiple daily insulin injections (MDI).
Diabetes 66 (Suppl 1): 932-P, 2017
102. Ahlén, E., Polonsky, W.H., Heise, T., Bolinder, J., Hirsch, I.B., Wedel, H., Hellman, J., Ólafsdóttir, A., Frid, A., Lind, M.
Variables associated with HbA1c improvement during CGM therapy in persons with T1D treated with multiple daily insulin injections (MDI).
Diabetes 66 (Suppl 1): 935-P, 2017
103. Kadzda, C., Löhr, J., Liu, R., Reddy, S., Dellva, M.A., Lim, S.T., Loh, M.T., Knadler, M.P., Hardy, T., Plum-Mörschel, L.
A novel formulation of insulin Lispro containing citrate and treprostinil shows faster absorption and improved postprandial glucose excursions vs. Humalog in patients with T1DM.
Diabetes 66 (Suppl 1): 959-P, 2017
104. Hardy, T.A., Andersen, G., Meiffren, G., Lamers, D., Ranson, A., Alluis, B., Gaudier, M., Soula, O., Kazda, C., Heise, T., Bruce, S.
Ultra-rapid BioChaperone Lispro (BCLIS) improves post-prandial blood glucose (PPG) excursions versus insulin lispro (LIS) in a 14-day treatment study in subjects with type 1 diabetes.
Diabetes 66 (Suppl. 1): 964-P, 2017
105. Kapitza, C., Leohr, J., Liu, R., Reddy, S., Dellva, M.A., Matzopoulos, M., Knadler, M.P., Loh, M.T., Hardy, T., Kadzda, C.
A novel formulation of insulin Lispro containing citrate and treprostinil shows significantly faster absorption and an improvement in postprandial glucose excursions vs. Humalog in patients with T2DM.
Diabetes 66 (Suppl. 1): 978-P, 2017

106. Bailay, T.S., Pettus, J., Roussel, R., Davis, S., Bergmann, K., Maroccia, M., Nassr, N., Klein, O., Bolli, G., Dahmen, R.
Insulin Glargine 300 U/mL (Gla-300) provides more even 24-hour pharmacokinetic (PK) and pharmacodynamic (PD) profiles vs. insulin degludec 100 U/mL (Deg-100) in T1DM.
Diabetes 66 (Suppl. 1): 985-P, 2017
107. Heise, T., Meiffren, G., Lamers, D., Kronshage, B., Ranson, A., Alluis, B., Gaudier, M., Anastassiadis, E., Kazda, C., Hardy, T.A., Soula, O., Bruce, S.
Ultra-rapid BioChaperone Lispro (BCLIS) improves post-prandial blood glucose (PPG) control versus insulin lispro (LIS) in a 14-day treatment study in subjects with type 2 diabetes.
Diabetes 66 (Suppl. 1): 994-P, 2017
108. Meiffren, G., Andersen, G., Klein, O., Ranson, A., Alluis, B., Gaudier, M., Linnebjerg, H., Ohwaki, K., Soula, O., Bruce, S.
Proportional dose-exposure relationship of ultra-rapid BioChaperone Lispro (BCLIS) in healthy Japanese subjects.
Diabetes 66 (Suppl. 1): 996-P, 2017
109. Hövelmann, U., Kronshage, B., Hermanski, L., Cöster, H.V., Heise, T., Rajendran Y.S., Al Zaher, T.
The human recombinant biphasic Julphar insulin 30/70 (JUL) is bioequivalent to Huminsulin Profil III (REF), an EU-marketed insulin.
Diabetes 66 (Suppl. 1): 1008-P, 2017
110. Heise, T., Tagore, R., Donnelly, C., Barve, A., Jacob, A.
Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of a proposed biosimilar insulin Glargine and Lantus in people with type 1 diabetes (T1D).
Diabetes 66 (Suppl. 1): 1019-P, 2017
111. Leelarathna, L., Thabit, H., Bally, L., Mader, J.K., Hartnell, S., Willinska, M.E., Dellweg, S., Benesch, S., Holzer, M., Kojzar, H., Qerimi-Hyseni, J. Evans, M.L., Arnolds, S., Pieber, T., Hovorka, R.
Comparison of closed-loop performance in individuals with lower and higher HbA1c.
Diabetes 66 (Suppl. 1): 1035-P, 2017
112. Forst, T., Plum-Mörschel, L., Alghdhan, K., Fischer, A., Kapitza, C., Heise, T.
Sequential treatment escalation with dapagliflozin and saxagliptin improves the insulin and glucagon balance during a hyperglycaemic clamp.
Diabetes 66 (Suppl. 1): 1247-P, 2017

52. Jahrestagung der Deutschen Diabetes Gesellschaft. Hamburg, Germany, May 24 – 27, 2017

113. Andersen, G., Meiffren, G., Alluis, B., Ranson, A., Soula, R., Gaudier, M., Soula, O., Kazda, C., Heise, T., Bruce, S.
Ultra-rapid BioChaperone Lispro ameliorates postprandial blood glucose (PPBG) in a group with diabetes mellitus.
Diabetologie und Stoffwechsel 12(S01): (P109), 2017
114. Ritzel, R., Bailey, T., Dahmen, R., Pettus, J., Roussel, R., Bergmann, K., Maroccia, M., Nassr, N., Klein, O., Bolli, G., Heise T.
Insulin glargin 300 E/ml (Gla-300) liefert stabilere und gleichmäßiger verteilte steady-state pharmakodynamische und pharmakokinetische Profile verglichen mit Insulin degludec bei Typ-1-Diabetes (T1DM).
Diabetologie und Stoffwechsel 12(S01): (P111), 2017
115. Küstner E., Grammes J., Demattio S., Kubiak T., Heinemann L.,
CSII bei älteren Typ-1-Diabetikern.
Insulin-Pumpenträger/innen und deren Erfahrungen im Krankenhaus.
Diabetologie und Stoffwechsel 12(S01): (P124), 2017
116. Hermanns, N., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Heinemann, L.
Kann man durch CGM-Profile Menschen mit Typ 1-Diabetes und einem hohen Risiko für schwere Hypoglykämien identifizieren? Erste Ergebnisse der Baseline-Erhebung der bundesweiten HypoDE-Studie.
Diabetologie und Stoffwechsel 12(S01): (P188), 2017
117. Forst, T., Plum-Mörschel, L., Alghdhan, M.K., Fischer, A., Kapitza, C., Heise, T.
Sequentielle Therapieeskalation mit Dapagliflozin und Saxagliptin verbessert die Insulinsekretion und den Glukagon - Insulin Quotienten im hyperglykämischen Clamp bei Patienten mit einem Diabetes mellitus Typ 2.
Diabetologie und Stoffwechsel 12(S01): (P206), 2017
118. Grammes, J., Küstner, E., Demattio, S., Heinemann L., Kubiak T.
Wünsche und Sorgen bezüglich einer altersgerechten Insulinpumpentherapie - Ergebnisse eines qualitativen Survey bei Menschen mit T1DM und Diabetesfachkräften.
Diabetologie und Stoffwechsel 12(S01): (P225), 2017

**10th International Conference on Advanced Technologies & Treatments for Diabetes.
Paris, France, February 15 – 18, 2017**

119. Bailey, T., Dahmen, R., Pettus, J., Roussel, R., Bergmann, K., Maroccia, M., Nassr, N., Klein, O., Bolli, G., Heise, T.
Insulin glargine 300 U/mL (GLA-300) provides more stable and more evenly distributed steady-state pharmacodynamic and pharmacokinetic profiles compared with insulin degludec in type 1 diabetes (T1DM).
Diabetes Technol. Ther. 19(S1): A-76, 2017

120. Kulzer, K., Daenschel, W., Daenschel, I., Parkin, C., Vesper, D., Messinger, J., Weissmann, L., Heinemann, L.
Awareness of type 2 diabetes therapy goals and perception of patient's health status: preliminary baseline results of the PDM pro-value studies.
Diabetes Technol. Ther. 19(S1): A-160, 2017

121. Heinemann, L., Daenschel, W., Parkin, C., Daenschel, I., Vesper, I., Messinger, D., Weissmann, J., Kulzer, B.
Quality of outpatient care of patients with type 2 diabetes: preliminary baseline results of the PDM pro-value studies.
Diabetes Technol. Ther. 19(S1): A-161, 2017

122. Leelarathna, L., Thabit, H., Hartnell, S., Willinska, M., Dellweg, S., Benesch, C., Mader, J., Holzer, M., Evans, M., Arnolds, S., Pieber, T., Hovorka, R.
Relationship between glucose variability and glycemic control during sensor-augmented pump therapy (SAP) and closed loop (CL) insulin delivery in adults with type 1 diabetes (T1D).
Diabetes Technol. Ther. 19(S1): A-172, 2017

Advanced Training Courses

Science Circle

- 123. Prof. Dr. Werner Kleophas
MZV DaVita, Düsseldorf, Germany
Diabetes and the kidney.
November 29, 2017

- 124. Dr. Jorge Arrubla
Profil GmbH, Neuss, Germany
Safety and efficacy of co-administered tesofensine / metoprolol in type 2 diabetes.
November 22, 2017

- 125. Dr. Grit Andersen
Profil GmbH, Neuss, Germany
Proof of the accuracy of the Atos-P system for continuous glucose monitoring.
November 22, 2017

- 126. Ulrike Hövelmann
Profil GmbH, Neuss, Germany
Pharmacokinetic and pharmacodynamic characteristics of a novel soluble and stable glucagon formulation.
November 22, 2017

- 127. Prof. Dr. Dirk Müller-Wieland
RWTH Aachen, Germany; Chair of the German Diabetes Association
PCSK-9-Antibodies: news about LDL-cholesterol and cardiovascular risk reduction.
September 6, 2017

- 128. Susan Clever, Dipl.-Psych.
Diabetes group practice Hamburg-Blankenese, Hamburg, Germany
Psychological aspects of diabetes.
May 31, 2017

- 129. Prof. Dr. Freimut Schliess
Profil GmbH, Neuss, Germany
Liver first? The liver in diabetes and cardiovascular disease.
May 3, 2017

130. Prof. Dr. Ralf Lobmann
Katharinenhospital Stuttgart, Germany
Medical Director
Diabetic foot – diabetic neuropathy.
April 14, 2017
131. Prof. Dr. Matthias Weber
Johannes Gutenberg Universität, Mainz, Germany
Diabetes mellitus and endocrinological conditions.
February 1, 2017
132. Dr. Tim Heise, Oliver Klein
Profil GmbH, Neuss, Germany
Pharmacodynamics and pharmacokinetics of long acting insulins – results from recent glucose clamp trials.
January 18, 2017

Trainings Clinical Pharmacology

- 133. Dr. Michael Reber
Hausärztezentrum Orpund, Switzerland
Psychosomatic bases.
December 1, 2017
- 134. Dr. Grit Andersen
Profil GmbH, Neuss, Germany
Patient-recruitment / inclusion and exclusion criteria.
November 16, 2017
- 135. Dr. Sabine Arnolds
Profil GmbH, Neuss, Germany
Patient-initiated research.
November 16, 2017
- 136. Claudia Huge
Profil GmbH, Neuss, Germany
Clinical trial equipment.
September 1, 2017
- 137. Antje Wieland
Profil GmbH, Neuss, Germany
Financial and contractual aspects of clinical trials.
July 1, 2017
- 138. Dr. Michael Reber
Hausärztezentrum Orpund, Switzerland
Psychosocial treatment effect modifiers – pharmacotherapy in the elderly.
June 16, 2017
- 139. Dr. Jorge Arrubla, Dr. Grit Andersen
Profil GmbH, Neuss, Germany
Clinical trials international.
June 8, 2017
- 140. Dr. Eric Zijlstra
Profil GmbH, Neuss, Germany
Diabetes medical technology.
April 24, 2017

141. Prof. Dr. Freimut Schliess
Profil GmbH, Neuss, Germany
Drug-induced liver injury.
March 31, 2017
142. Dr. Grit Andersen
Profil GmbH, Neuss, Germany
The draft guideline early clinical trials.
March 31, 2017
143. Dr. Grit Andersen
Profil GmbH, Neuss, Germany
Environmental influences on health.
March 9, 2017

Granted Research Consortia

144. EIT Health e.V. and German EIT Health GmbH.

A Knowledge and Innovation Community (KIC) on Healthy Living and Active Ageing, funded by the European Institute of Innovation and Technology (EIT).
First funding period: 2015 – 2022
<http://eithealth.eu/>

Profil GmbH is EIT Health core partner and a full voting member of the EIT Health e.V. Partner Assembly.

Profil GmbH is represented in the German EIT Health GmbH Supervisory Board.

EIT Health innovation project by design:

CLOSE: Automated Glucose Control at Home for People with Chronic Disease.



Members of the CLOSE Consortuim & guests
Going AP+ value concept design workshop. IESE Business School. Barcelona, Spain, July 10-11, 2017

Funding period: July 2016 – June 2020

Involved EIT Health partners: Air Liquide Healthcare, Sanofi, Profil GmbH, IESE Business School, Katholic University Leuven, Medical University of Lodz.

Additional project partners: Cellnovo, Aqua Institute for Applied Quality Improvement and Research in Health Care, Eurice, Forschungsverein Mechatronischer Systeme Linz

Coordinating organisation: Profil GmbH

EIT Health Summer School:

Digital innovation in diabetes care (InnoDiaCare)

Part 1: Medical University of Lodz, Poland, July 2 – 8, 2017,

Part 2: University of Cologne, Germany, August 28 – September 2, 2017

Funding period: January 2017 – December 2017

Involved EIT Health partners: Air Liquide Healthcare, Bayer, Miltenyi, Profil GmbH, Roche Diagnostics GmbH, IESE Business School, Katholic University Leuven, Medical University of Lodz.

Additional partners: Eurice, Heimdall Combat Systems, Lodz University of Technology (DT4U- design thinking workspace)

Coordinating organisation: Medical University of Lodz



Participants of the InnoDiaCare EIT Health Summer School on Digital Innovation in Diabetes Care - Part 1, Medical University of Lodz, Poland, July 2 – 8 , 2017

EIT Health innovation project by design:

Clinical validation of an interconnected disease management system for people with diabetes in Europe (ClassIDM).

Funding period: January 2017 – December 2018

Involved EIT Health partners: Becton-Dickinson, Bull, Profil GmbH, Université Grenoble Alpes.

Coordinating organisation: Becton-Dickinson

EIT Health innovation project by idea:

Diabeloop for kids (D4kids).

Funding period: January 2018 – December 2018

Involved EIT Health partners: Commissariat à l'énergie atomique et aux énergies alternatives - laboratoire d'électronique des technologies de l'information (CEA-Leti), Profil GmbH, Katholic University Leuven

Additional partners: Diabeloop, Ceritd

Coordinating organisation: CEA-Leti

145. **Competence Center for Biomarker Research in Medicine.**

COMET K1 Center for Biomarker Research at CBmed.

Funded by the Austrian Research Promotion Agency

First funding period: 2015 – 2019

<http://www.cbmed.org/en/index.php>

Profil GmbH is chairing the consortium board of the CBmed GmbH.

Profil GmbH is part of the project area "Metabolism & inflammation"

Project 3.6

Minimally invasive biomarkers for liver function.

Funding period: June 2015 – December 2018

146. **Regional Innovation Network (RIN) Diabetes.**

Funding: Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein Westfalen.

Funding period: 2014 – 2017

<http://www.rin-diabetes.de/>

147. **SPIDIMAN – Single-Port Insulin Infusion for Improved Diabetes Management.**

EU Project 7th Framework Programme, contract no. 305343

European Project to Combine Glucose Monitoring and Insulin Infusion in a Single Needle.

Funding period: November 2012 – December 2016

<http://www.spidiman.eu/>

Scientific Communication

Webinars

<http://www.profil.com/knowledge-center/webinars>

- 148. **Digitalisation in Diabetes.**
L. Heinemann. October 12, 2017
- 149. **Advances in insulin pump therapies.**
E. Zijlstra. July 25, 2017
- 150. **First in human trials: scientific considerations.**
G. Andersen, J. Arrubla. May 30, 2017
- 151. **Determining energy expenditure in clinical trials.**
D. Lamers. March 9, 2017



Blogs

<http://blog.profil.com/blog>

152. **Health claims and the need for scientific evidence in food studies.**
D. Lamers. December 13, 2017
153. **The need for speed.**
E. Zijlstra. December 1, 2017
154. **“Profil World” – the clinical diabetes research newsletter – November 2017**
T. Dicenzo. November 23, 2017
155. **Treatment with SGLT2 inhibitors: is there hope for renal protection?**
J. Arrubla. November 17, 2017
156. **Can a dual-hormone closed loop delivery system become a “technical cure” of diabetes?**
U. Hövelmann. November 2, 2017
157. **Biomarkers for vascular integrity in patients with diabetes mellitus. Part 2: microvascular function.**
T. Forst. October 29, 2017
158. **Insulin therapy: Profil presented at EASD 2017.**
T. Dicenzo. October 20, 2017
159. **Novelties in the treatment of type 2 diabetes presented at the EASD 2017.**
J. Arrubla. October 12, 2017
160. **Minimal blood loss with automated glucose clamps: a new configuration of ClampArt®.**
C. Benesch. October 4, 2017
161. **Non-invasive liver fat and liver stiffness screening at Profil.**
G. Andersen. September 28, 2017
162. **Alternate – day fasting: any better than other diets?**
D. Lamers. September 12, 2017
163. **Inhaled insulins - a valid option in the treatment of diabetes?**
T. Herbrands. September 4, 2017
164. **HbA1c, a diabetes marker for the past and for the future?**
E. Zijlstra. August 28, 2017

165. **Free webinar on digitalization in diabetes by Prof. Lutz Heinemann. Why should you care about digitalization in diabetes care?**
L. Bochmann. August 23, 2017
166. **One insulin tablet a day... Profil study shows promise for alternative to insulin injections.**
T. Dicenzo. August 22, 2017
167. **Biomarkers for vascular integrity in patients with diabetes mellitus. Part 1: macrovascular function.**
T. Forst. August 17, 2017
168. **Glucose clamps: 2 steps towards hepatic and peripheral insulin sensitivity.**
F. Schliess. August 9, 2017
169. **"Profil World" – the clinical diabetes research newsletter - July 2017.**
T. Dicenzo. August 2, 2017
170. **Error Grid Analysis.**
C. Benesch. July 27, 2017
171. **Update to the EU Directive 536/2014 and Brexit.**
G. Andersen. July 21, 2017
172. **Looking beyond blood glucose - the islet of Langerhans.**
T. Forst. July 4, 2017
173. **Considering the complexity of food – drug interactions for drug development.**
T. Herbrand. June 28, 2017
174. **Smart insulin patches or glucose-responsive insulin delivery systems.**
U. Hövelmann. June 21, 2017
175. **A different design of glucose clamps: fixed rate of blood glucose change rather than fixed blood glucose levels.**
C. Benesch. June 13, 2017
176. **Targeting LDL cholesterol – how low do we need to get it? And at what price?**
O. Klein. June 1, 2017
177. **Don't miss ADA 2017 President's Oral Session. Profil will be all over the conference.**
T. Dicenzo. June 1, 2017
178. **Will noninvasive glucose monitoring end in tears?**
E. Zijlstra. May 24, 2017

179. **Meet us at the MedTech Summit 2017.**
T. Dicenzo. May 16, 2017
180. **First in Human (FIH) trials: new draft guideline for risk mitigation.**
G. Andersen. May 16, 2017
181. **New study about sugar vs. calorie-free sweeteners.**
D. Lamers. May 10, 2017
182. **InnoDiaCare: Summer School for Digital Innovation in Diabetes Care.**
F. Schliess. May 5, 2017
183. **"Profil World" - The clinical diabetes research newsletter - April 2017.**
T. Dicenzo. April 25, 2017
184. **Profil recent publications on diabetes.**
T. Dicenzo. April 20, 2017
185. **How clinical trial results are distorted by reporting bias.**
S. Arnolds. April 13, 2017
186. **Your blood glucose meter might not be sufficiently accurate! (Update 03/2017).**
E. Zijlstra. April 6, 2017
187. **How do SGLT2 inhibitors improve cardiovascular outcomes?**
J. Arrubla. March 31, 2017
188. **Patient-initiated research – how involvement of patients could help improve diabetes research.**
S. Arnolds. March 24, 2017
189. **Glucose clamps: 2 steps towards insulin sensitivity adjusted for glucose effectiveness.**
F. Schliess. March 16, 2017
190. **The new Clinical Trials Regulation EU No 536/2014 - amendments to the German Drug Law.**
G. Andersen. March 9, 2017
191. **New Biosimilar Insulin study published – Profil is an expert on biosimilar insulins.**
L. Bochmann. March 2, 2017
192. **Oral insulins still under development.**
L. Bochmann. February 23, 2017

193. **Profil Webinar Series on Diabetes and Obesity.**
T. Dicenzo. February 16, 2017
194. **"Profil World" – The clinical diabetes research newsletter's January 2017 edition.**
T. Dicenzo. February 1, 2017
195. **Improved algorithm for automated glucose clamps.**
C. Benesch. January 10, 2017

Media Reports (Selection)

- 196. **Interview: CLOSE crosses EIT Health pillars to ‘close the loop’ for diabetes patients**
EIT Health News, January 10, 2018
- 197. **Trend-Seminar – Digital Innovation in Diabetes Care. Merging innovation and entrepreneurial education to tackle diabetes care.**
EIT Health Success Story, December 6, 2017
- 198. **EIT Health partner Profil appoints Professor Hans deVries as senior medical scientist.**
EIT Health News, November 24, 2017; EIT Health Germany News, November 1, 2017
- 199. **Successful completion of InnoDiaCare – the EIT Health Summer School on Digital Innovation in Diabetes Care.**
EIT Health News, September 6, 2017



Participants of the InnoDiaCare EIT Health Summer School on Digital Innovation in Diabetes Care – Part 2, University of Cologne, Germany, August 28 – September 2, 2017

- 200. **Insulin als Tablette erfolgreich getestet.**
DiabSite, July 31, 2017
- 201. **Successful start of InnoDiaCare – the EIT Health Summer School on Digital Innovation in Diabetes Care.**
EIT Health News, July 26, 2017

- 202. **Proband werden und selbst profitieren. Diabetesforschung – jeder kann helfen.**
Sächsische Zeitung (sz-online.de), June 8, 2017
- 203. **Deutsche Studie mit integriertem closed-loop System am Profil Institut in Neuss.**
Suess, happy und fit, February 16, 2017
- 204. **Warten auf die künstliche Bauchspeicheldrüse.**
Diabetes Ratgeber, February 2, 2017
- 205. **Tim Heise.**
JDRF typeonenation, January 11, 2017